...
首页> 外文期刊>Scandinavian journal of rheumatology >Henoch-Schonlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment.
【24h】

Henoch-Schonlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment.

机译:过敏性紫癜性肾炎合并肾病范围蛋白尿:可能与环孢菌素A和类固醇治疗有关的组织学消退。

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To clarify the therapeutic role of cyclosporin A (CyA) for patients with Henoch-Schonlein purpura nephritis (HSPN) showing nephrotic-range proteinuria.Methods: The clinical and histological findings of eight children (7.7+/-3.8 years), who were treated with CyA and prednisolone, were evaluated retrospectively. All underwent a renal biopsy before therapy, and six of the eight patients received a follow-up biopsy after therapy.Results: The histological grade of the International Study of Kidney Disease in Children (ISKDC) was improved in all six patients who received a follow-up biopsy (pre-therapy, four grade IIIa and two grade IIIb; post-therapy, one grade I and five grade II) and it was statistically significant (p = 0.031). The activity index was significantly decreased after therapy (8.3+/-1.6 vs. 3.5+/-1.5, p = 0.031), and the chronicity index (0.5+/-0.5 vs. 0.7+/-1.0) and tubulointerstitial (TI) scores (1.5+/-1.3 vs. 0.8+/-1.6) did not change. There was a reduction in proteinuria from 3.2+/-2.3 to 0.1+/-0.1 g/m(2)/day (p = 0.008) and renal function remained normal in all patients after therapy. However, one patient showed CyA-induced nephrotoxicity at a second biopsy. After an average follow-up period of 3.8 years, six patients showed normal urine and renal function, and two showed minor urinary abnormalities.Conclusion: This study suggests that CyA therapy is effective in reducing proteinuria, which is a known risk factor for the development of renal insufficiency in HSPN and may regress the renal pathology in patients with nephrotic-range proteinuria.
机译:目的:阐明环孢菌素A(CyA)对表现为肾病性范围性蛋白尿的过敏性紫癜性肾炎(HSPN)患者的治疗作用。方法:对8名7.7±3.8岁儿童进行临床和组织学检查接受CyA和泼尼松龙治疗,进行回顾性评估。所有患者均在治疗前进行了肾脏活检,并且在八名患者中有六名在治疗后接受了随访活检。结果:接受随访的所有六名患者的国际儿童肾脏病研究(ISKDC)的组织学评分均得到改善活检(治疗前,四个IIIa级和两个IIIb级;治疗后,一个I级和五个II级),具有统计学意义(p = 0.031)。治疗后活动指数显着降低(8.3 +/- 1.6 vs.3.5 +/- 1.5,p = 0.031),慢性指数(0.5 +/- 0.5 vs. 0.7 +/- 1.0)和肾小管间质(TI)分数(1.5 +/- 1.3与0.8 +/- 1.6)没有变化。治疗后所有患者的蛋白尿均从3.2 +/- 2.3降至0.1 +/- 0.1 g / m(2)/天(p = 0.008),并且肾功能保持正常。然而,一名患者在第二次活检中显示出CyA诱导的肾毒性。平均随访3.8年后,有6例患者尿液和肾功能正常,其中2例尿液异常。结论:这项研究表明CyA疗法可有效降低蛋白尿,这是导致发育的已知危险因素肾功能不全患者的肾功能不全,可能使肾病范围蛋白尿患者的肾脏病理恶化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号